Professor Costantino Pitzalis Honoured with Prestigious ACR Master Designation and Presents Breakthrough Research at ACR 2026
The Centre for Experimental Medicine & Rheumatology (EMR) at Queen Mary University of London is proud to announce that Professor Costantino Pitzalis has been conferred as a Master of the American College of Rheumatology (MACR) for 2026. The designation of Master is one of the highest honours bestowed by the American College of Rheumatology. It is awarded to distinguished members age 65 or older who have made outstanding, lifelong contributions to the ACR and the field of rheumatology through scholarly achievement, clinical innovation, and dedication to education and service.
/filters:format(webp)/prod01/channel_144/whri/media/the-william-harvey-research-institute/ACR-Master-Award-Pic.JPG)
The Centre for Experimental Medicine & Rheumatology (EMR) at Queen Mary University of London is proud to announce that Professor Costantino Pitzalis has been conferred as a Master of the American College of Rheumatology (MACR) for 2026. The designation of Master is one of the highest honours bestowed by the American College of Rheumatology. It is awarded to distinguished members age 65 or older who have made outstanding, lifelong contributions to the ACR and the field of rheumatology through scholarly achievement, clinical innovation, and dedication to education and service.
Reflecting on this recognition, Professor Pitzalis stated, “Receiving the ACR Master designation is a deeply humbling honour, reflecting a lifetime dedicated to advancing rheumatology through research, education and patient care. It reaffirms my commitment to translating discovery science into clinical innovation, improving patient care through the integration of molecular pathology into clinical management algorithms, and inspiring the next generation of translational clinicians and scientists.”
Alongside receiving this honor, Professor Pitzalis presented as the presenting author in two key sessions at the meeting on Sunday, November 8, 2026. During the Plenary I session, he presented “Rosnilimab Selectively Depletes Pathogenic T Cells and Downregulates Clinically Relevant Immune Pathways in Rheumatoid Arthritis: A Translational Analysis of Blood and Synovial Tissue from the Phase 2B Trial”. Later that afternoon, in the session Rheumatoid Arthritis - Translational Models and Mechanisms, he presented “Early Synovial Immune Landscape Is Associated With 5-years Outcomes In Rheumatoid Arthritis”.
The Centre extends its warmest congratulations to Professor Pitzalis on this well-deserved recognition and his ongoing contributions to translational rheumatology.
Further details regarding the 2026 Masters Class can be found on The Rheumatologist website.
